期刊文献+

美国医师—药业关系的监管及启示分析

下载PDF
导出
摘要 概述美国联邦政府涉及到医师—药业业关系的监管部门、法律依据及行为指南,列举典型案例阐述相关法规在实际中的运用,分析现有规章制度对医师—药业业关系产生的影响、存在的问题,以及对我国的启示。结果表明:在细致完善行业行为指南的基础上,职能部门需要加强监管,甚至考虑单独立法,同时公立机构应承担更多临床研究、医师教育和培训的职责,为我国医师—药业业关系(Physician Industry Relations)的研究与管理提供参考。
出处 《现代商贸工业》 2012年第15期163-165,共3页 Modern Business Trade Industry
  • 相关文献

参考文献22

  • 1张忠鲁,徐立新.医生与药业的关系:利益冲突重要根源[J].医学与哲学(A),2007,28(7):6-11. 被引量:8
  • 2Relman A. Separating continuing medical education from pharmaceutical marketing[J]. JAMA,2001, (285) :2009-2014.
  • 3Yue Wang, Ron A. Adelman. A Study of Interactions between Pharmaceutical Representatives and Ophthalmology Trainees[J]. Pharmaceutical Industry and Residents, 2009,184(4):619-622.
  • 4BlumenthalD. Dotters and drug companies[J]. NEJM, 2004, (351), 1885-1890.
  • 5Sieries F S,Brodkey A C,Clearly L M,et al. Medical students' exposure to and attitudes about drug company interactions:a national survey[J]. JAMA, 2005, (294) : 1034-1042.
  • 6Nissen S,Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death/rom cardiovascular causes[J]. N Engl J Med,2007,356 (24) :2457-2471.
  • 7Rosen C. The rosiglitazone story-lessons from an FDA advisory committee meeting[J]. N Engl J Med,2007,357 (9) : 844-846.
  • 8Steinman MA, Bero LA,Chresn M,Landefeld CS. Narrative re- view. The promotion of gabapentin:an analysis of internal indus- try doeuments[J]. Ann Int Med,2006,145(4) :284-293.
  • 9Sara T. M. Kremer, Tammo H. A. Bijmoh, Peter S. H. Leeflang, Jaap E. Wieringa[J3. Intern. J. of Research in Marketing, 2008, (25) ,234-246.
  • 10Spencer D. Dorn,JoeI F. Farley, Richard A. Hansen, Nilay D. Shah,Robert S. Sandier. Direct-to-Consumer and Physician Pro- motion of Tegaserod Correlated With Physician Visits, Diagno-ses,and Prescriptions[J]. Gastroenterology, 2009,137 (2) : 518- 524.

二级参考文献43

  • 1Campbeel E G, Gruen R L, Mountford J, et al. A national survey of physician- industry relationships[J]. NEJM,2007, (356) : 1742 - 50.
  • 2Wazana A. Physicians and the pharmaceutical industry: is a gif ever just a gift? [J]. JAMA, 2000, (283) : 373 - 80.
  • 3Relman A. Separating continuing medical education from pharmaceutical marketing[J]. JAMA,2001, (285) :2 009 - 2 014.
  • 4Blumenthal D. Docters and drug companies[ J ]. NEJM, 2004, (351) : 1 885- 1 890.
  • 5Rawlins M D. Doctors and the drug makers[J]. Lancet, 1984, (2) :276 - 278.
  • 6Kein S M, Mays M Z, Grant D. Interactions between emergency medicine programs and the pharmaceutical industry [ J ]. Acad Emerg Med,2004, (11):19 - 26.
  • 7Komesaroff P A,Kerridge I H. Ethical issues concerning the relationshis between medical practitioners and the pharmaceuteical industry [J]. Med J Aust,2002, (176) : 118 - 121.
  • 8Campbeel E G, Gruen R L, Mountford J, et al. A national survey of physician - industry relationships [ J ] NEJM, 2007, ( 356 ) : 1 742 - 1 750.
  • 9Sieries F S,Brodkey A C,Clearly L M,et al. Medical students'exposure to and attitudes about drug company interactions:a national survey [J].JAMA,2005,(294):1 034- 1 042.
  • 10Campbell E G,Weissman J S,Vogeli C, et al . Finsneial relationships between institutional review board members and industry[J]. NEJM, 2006, (355) :2 321 - 2 329.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部